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Abstract: Since HIV was first identified, and in a relatively short period of time, AIDS has become
one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies
were a major step forward in disease treatment options, significantly improving the survival rates of
HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes,
antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous
solubility, short half-life, and poor penetration into HIV reservoir sites, which contribute to the
suboptimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based
strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review is
focused on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties
of ARV to overcome biological barriers upon administration. Furthermore, a correlation between
these properties and the potential therapeutic outcomes has been established. Biotechnological
advancements using lipid nanocarriers for RNA interference (RNAi) delivery for the treatment of
HIV infections were also discussed.
Keywords: ARV delivery; biotechnology in ARV; biological barriers; lipid emulsions; lipid nanoparticles;
liposomes; RNAi and ARV codelivery
1. Introduction
The human immunodeficiency virus (HIV) is known to promote the continuous dete-
rioration of the host immune system, being responsible for the acquired immunodeficiency
syndrome (AIDS) [1,2]. According to the Joint United Nations Program on HIV infec-
tion/AIDS (UNAIDS), by the end of 2018, the epidemic accounted for more than 30 million
deaths worldwide with a particular incidence in the female population and Sub-Saharan
African countries [3]. Currently, 37.9 million people are infected with the virus and only a
fraction (≈82%) have access to antiretroviral (ARV) therapy [3].
ARVs revolutionized HIV infection/AIDS clinical history and their approval for ther-
apeutic purposes transformed this condition into a chronically manageable disease [4].
ARV-based therapies continue to be the best treatment option against HIV infection/AIDS
providing prolonged viral suppression and, consequently, lower mortality rates [5,6]. The
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first treatments were based on monotherapy regimens which rapidly led to the devel-
opment of ARV resistance [7,8]. Consequently, novel strategies were adopted, namely,
combined antiretroviral therapy (cART; formerly referred to as highly effective antiretrovi-
ral therapy (HAART)) based on the simultaneous administration of three or more different
classes of drugs [7,8].
Although HIV infection/AIDS stands as a public health concern, anti-HIV therapies
have greatly increased the life quality and expectancy of infected individuals [9]. However,
these therapies are challenging and often difficult to implement in the developing world.
Multiple factors may compromise their success, such as: (i) adverse effects associated with
the multi-regimen therapies extended over long periods; (ii) development of viral resis-
tance; (iii) ineffective viral suppression due to low drug concentrations in viral reservoirs;
(iv) pharmacokinetic problems and possible interactions between drugs; (v) poor stability
and reduced shelf-life; (vi) low patient adherence; (vii) unbearable high costs for most of
the populations in need, and (viii) socio-cultural constraints that limit the access to these
treatments [10,11].
In the last decades, several strategies to improve HIV disease management using
nanotechnology have emerged and seen tremendous growth both in treatment and pre-
vention. Nanotechnology-based systems radically changed the global medical scheme and
gained considerable attention in therapeutic research. In particular, nanomedicine-based
approaches may help to improve pharmacokinetic problems (e.g., low oral bioavailability
or short half-life) of ARV drugs [9,12–21]. Poor aqueous solubility is another common
problem transversal to many drugs, which can be improved by encapsulation in drug
carriers [22]. The reduction of the particles size to the nanometric scale increases the surface
area available for solvation which has shown to be an effective strategy to increase drug
solubility and, consequently, improve oral bioavailability [23]. Another interesting feature
brought by nanomedicine is the ability to modulate the drug release profiles to occur over
a longer time and at higher effective doses to the specific sites [8,22]. Moreover, toxicity
associated with ARV therapies may also be circumvented using drug-loaded systems. A
possible explanation is the controlled release profiles obtained with nanocarriers, reducing
the toxicity namely at the cellular level [2].
The encapsulation of ARV drugs is particularly interesting as a targeting strategy
towards cellular and anatomic HIV reservoirs and it can be achieved either by passive or
active targeting [2,8]. In the first case, the targeting is dependent on nanocarriers’ intrinsic
properties such as mean diameter, surface properties (e.g., charge), and shape [2]. On
the other hand, active targeting typically depends on the functionalization of the carrier
surface with ligands that recognize receptors at the targeted tissues [2,9]. Furthermore,
these carriers act as protective shields against external threats (e.g., chemical and enzymatic
degradation) leading to increasing residence periods of ARV in the organism [9]. This
feature may promote the reduction of required doses and, consequently, prolong time
intervals between administrations [2]. Ultimately, it is possible to encapsulate different
types of therapeutic payloads within the same system which can contribute to simpler
administrations increasing patient adherence but also reduce possible errors related to
therapeutic regimens [2,24].
Among the multiple nanocarriers that can be used for ARV delivery, lipid-based
nanocarriers hold great promise since 15 of the 21 marketed approved nanomedicines are li-
posomes or lipid nanoparticles (AmBisome®, DaunoXome®, DepoCyt®, DepoDur®, Doxil®,
Inflexal® V, Marqibo®, Mepact®, Myocet®, Visudyne®, Abelcet®, Amphotec®, Fungizone®,
Diprivan®, Estrasorb®) [25]. Of particular notice, this list has been recently upgraded with
the introduction in the market of nucleoside-based nanomedicines for the treatment of
hereditary transthyretin-mediated amyloidosis (Onpattro®) and prophylaxis of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (Pfizer/BioNTech Comirnaty®
and the Moderna COVID-19 vaccines). Furthermore, these carriers are well-accepted in
the scientific community for therapeutic purposes mainly because their structural units
are generally recognized as safe (GRAS) [25]. Additionally, lipids’ biocompatibility and
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biodegradability properties as well as their versatility make them suitable and safe de-
livery systems for humans, with low or non-associated toxicity [11,26]. A large number
of lipid-based nanocarriers developed for ARV delivery justifies a constantly updated
review. Even though some reviews have covered this topic [27–29], it is important to
address some neglected aspects regarding the details of formulation development to serve
as a guide for researchers working in this field. To the best of our knowledge, no similar
reviews have considered the composition and characterization of lipid nanocarriers in
terms of size, colloidal stability, encapsulation, and drug loading efficiency, as well as
establishing a correlation between the nanocarriers’ physicochemical properties and their
potential anti-HIV therapeutic outcomes. Moreover, biotechnological applications of lipid
nanocarriers loaded with anti-HIV therapeutics will be presented including the use of
lipoplexes for small interference ribonucleic acid (siRNA) delivery and other interesting
prospects for other disease conditions (e.g., neurodegenerative diseases) that have not yet
been considered. For example, considering that reverse transcriptase (RT) is found in a
variety of human cells, including those in the brain, and that it is involved in somatic gene
recombination (SGR), which is linked to dysregulated neuronal genomes in Alzheimer’s
disease (AD), the inhibition of this enzyme by ARV agents in combination with siRNA-
mediated silencing of its expression is considering a promising biotechnological approach
for the prevention and/or treatment of this neurodegenerative disease. The utilization
of lipid-based nanocarriers for co-delivery ARV and siRNA aids to cross the brain-blood
barrier (BBB).
2. ARV Agents: Mechanism of Action and Limitations
Following the isolation and subsequent identification of HIV as the main agent re-
sponsible for the onset of HIV infection/AIDS, significant progress was made, allowing for
a detailed characterization of the virus and its life cycle, as well as a better understanding
of the mechanisms underlying its mode of action [30]. In this way, it became possible
to identify new, highly specific pharmacological targets in the HIV life cycle (Figure 1)
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Figure 1. Stages in HIV lifecycle. (1) HIV attaches to CD4 receptor and CCR5 co-receptor. (2) HIV
gp41 is exposed to the host cell and causes fusion. (3) HIV enters the nucleus and releases its enzymes
and RNA. (4) Reverse transcriptase makes a double strand HIV DNA from HIV RNA. (5) Integrase
includes HIV DNA in the DNA of the host cell. (6) New HIV viral components are produced, and
Protease assembles new HIV virus. (7) Each host cell produces hundreds of new virions.
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In 1987, zidovudine (AZT) was approved as the first ARV for therapeutic use. Since
then, and in a short period, 6 more classes of ARVs have been developed and, to date,
49 medicines containing single ARV drugs or drug associations (as in the case of cART)
have been approved and made available on the market by the United States Food and
Drug Administration (U.S. FDA) for the clinical treatment of HIV infection/AIDS [31]. The






















Figure 2. Molecular components of HIV virus and targets of ARV drugs. In the virus, the targets can be the glycoproteins
responsible for adhesion gp120 and gp41; the enzymes integrase, reverse transcriptase, a d prot ase; th protein from the
capsid p24 and protein Tat that modulates transcription initiation and can reactivate a latently infected cell by penetrating.
In the host cells the targets can be the lymphocyte function-associated antigen 1 (LFA-1); the CD4 receptor and its co-receptor









Figure 4. Reverse  transcriptase  (RT)  inhibitors. Red  arrows  represent  the nucleoside  reverse  transcriptase  inhibitors 
(NRTI):  lamivudine  (3TC);  abacavir  (ABC);  zidovudine  (AZT);  stavudine  (d4T);  didanosine  (ddI);  zalcitabine  (ddC); 
emtricitabine (FTC); tenofovir disoproxil fumarate (TDF). Purple arrows represent the non‐nucleoside reverse transcrip‐
tase inhibitors (NNRTI): efavirenz (EFV); etravirine (ETR); nevirapine (NVP); delavirdine (DLV). 
Figure 3. Cell entry inhibitors and fusion inhibitors. Ibalizumab-uiyk (IBA) blocks CD4 and maraviroc (MVC), blocks CCR5
receptors from host cells. Enfuvirtide (T-20) blocks gp41 and fostemsavir tromethamine (FTR) blocks gp120 from the virus.









Figure 4. Reverse  transcriptase  (RT)  inhibitors. Red  arrows  represent  the nucleoside  reverse  transcriptase  inhibitors 
(NRTI):  lamivudine  (3TC);  abacavir  (ABC);  zidovudine  (AZT);  stavudine  (d4T);  didanosine  (ddI);  zalcitabine  (ddC); 
emtricitabine (FTC); tenofovir disoproxil fumarate (TDF). Purple arrows represent the non‐nucleoside reverse transcrip‐
tase inhibitors (NNRTI): efavirenz (EFV); etravirine (ETR); nevirapine (NVP); delavirdine (DLV). 
Figure 4. Reverse transcriptase (RT) inhibitors. Red arrows represent the nucleoside reverse transcriptase inhibitors (NRTI):
lamivudine (3TC); abacavir (ABC); zidovudine (AZT); stavudine (d4T); didanosine (ddI); zalcitabine (ddC); emtricitabine
(FTC); tenofovir disoproxil fumarate (TDF). Purple arrows represent the non-nucleoside reverse transcriptase inhibitors














Figure 5. Integrase inhibitors: raltegravir (RAL); dolutegravir (DTG); elvitegravir (EVG); cabotegravir (CAB).














Figure 6. Protease inhibitors: tipranavir (TPV); indinavir (IDV); ritonavir (RTV); fosamprenavir (FPV); atazanavir (ATV);
lopinavir (LPV); saquinavir (SQV).
Thus, ARV can be grouped into the following therapeutic classes (Table 1): cell entry
inhibitors (stage 1 of Figures 1 and 3; fusion inhibitors (FI) (stage 2 of Figures 1 and 3;
nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI)
(stage 4 of Figures 1 and 4); integrase inhibitors (IIs) (stage 5 of Figures 1 and 5); and protease
inhibitors (PI) (stage 6 of Figures 1 and 6) [31,32]. Pharmacokinetic enhancing drugs
(e.g., cobicistat) can also be used in association with ART agents to improve therapeutic
effectiveness.
Table 1. ARV agents are classified into therapeutic classes based on their mechanism of action and target site [31,33,34].
ARV Therapeutic Class Mechanism of Action ARV Single Agents andSome ARV Associations
Cell entry inhibitors
CCR5 antagonists
Block CCR5 coreceptors present on
the surface of specific immune cells,




Bind to the gp120 protein on the
viral outer surface, blocking HIV
entry into CD4 cells.
FTR
Post-attachment inhibitors
Block CD4 receptors present on the
surface of specific immune cells,




Interferes with HIV binding, fusion,
and cell entrance by preventing the
gp41 glycoprotein from being
exposed to the virus-host cell
membrane.
T-20
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Table 1. Cont.
ARV Therapeutic Class Mechanism of Action ARV Single Agents andSome ARV Associations
Nucleoside reverse transcriptase inhibitors (NRTI) Block the viral RT, inhibiting HIVreplication.
3TC; ABC; AZT; d4T; ddI; ddI
EC; ddC (F.M.); FTC; TDF;
3TC+AZT; ABC+3TC;
ABC+AZT+3TC; TDF+FTC
Non-nucleoside reverse transcriptase inhibitors (NNRTI) Bind to viral RT and subsequentlymodify it, limiting HIV replication.
DOR; EFV; RPV; ETR; NVP;
DLV
Integrase inhibitors (II)
Inhibition of viral integrase.
Prevents the incorporation of HIV
proviral DNA strands into the host
cell genome.
RAL; DTG; EVG; CAB
Protease inhibitors (PI)
Inhibition of viral protease.
Prevents the cleavage of some viral
proteins and the maturation of
virions, resulting in non-viral
particles.
TPV; IDV; RTV; DRV; FPV;
ATV; LPV+RTV; SQVM+RTV
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; CAB, cabotegravir; CCR5, C-C chemokine receptor type
5; CD4, cluster of differentiation 4; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; ddI EC, enteric coated didanosine; DLV, delavirdine;
DNA, deoxyribonucleic acid; DOR, doravirine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; FI,
fusion inhibitors; FPV, fosamprenavir; FTC, emtricitabine; FTR, fostemsavir tromethamine; gp41, glycoprotein gp41; gp120, glycoprotein
gp120; HIV, human immunodeficiency virus; IBA, ibalizumab-uiyk; IDV, indinavir; II, integrase inhibitors; LPV, lopinavir; MVC, maraviroc;
NNRTI, non-nucleoside reverse transcriptase inhibitors (NRTI, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; PI, protease
inhibitors; RAL, raltegravir; RT, reverse transcriptase; RPV, rilpivirine; RTV, ritonavir; SQVM, saquinavir mesylate; T-20, enfuvirtide; TDF,
tenofovir disoproxil fumarate; TPV, tipranavir.
Despite the recognized overall success of cART, particularly in developing countries,
this therapeutic strategy continues to raise some important issues, and its effectiveness is
affected by several limitations. For example, the multi-dose treatments administered over
extended periods can result in the development of ARV resistance mechanisms and can also
lead to the inability to effectively suppress the virus due to the difficulties in maintaining
consistent drug levels, particularly in viral reservoirs [8,35]. The mechanisms underlying
ARV resistance are often related to HIV genetic variability and HIV reverse transcriptase
processing errors. This high mutation rate coupled with the virus’s fast replication leads to
the creation of innumerable virus variants (quasispecies) capable of avoiding the immune
system [36,37]. Additionally, the recombination of more than one viral strain during
infection or the accumulation of proviral variants also contribute to viral resistance [37,38].
Although some HIV variants display primary mutations that make them less susceptible
to ARV action, most ARV resistance results from direct exposure to these regimens and it
was already observed in all six therapeutic classes through different mechanisms [36]. For
example, in NRTI, whose main function is to block the viral RT and inhibit HIV replication,
resistance can occur by two mechanisms. The first mechanism corresponds to mutations
at or near the drug-binding site of RT (e.g., M184V, L74V, K65R, and others) leading to a
conformational change in the enzyme that ultimately blocks the binding of NRTI to the
active site [36,39]. Such a mechanism enables viral RT to discriminate between dideoxy-
NRTI chain terminators and endogenous triphosphate deoxynucleosides, preventing the
binding of NRTI to viral DNA [37] The second mechanism corresponds to phosphorylytic
removal of NRTI-triphosphate from its site of attachment in the viral DNA chain [36,37].
These mutations are characteristic of the thymidine analogs (AZT and d4T) and can also be
described as thymidine analog mutations (TAM). TAM can be further divided into type I
(e.g., M41L, L210W, and T215Y) and II (e.g., D67N, K70R, T215F, and K219Q/E), however,
type I is responsible for higher levels of phenotypic and clinical cross-resistance [37].
The most frequent mutations that occur in NNRTIs, take place within their binding
pocket and mostly affect hydrophobic residues of HIV-RT [36,40]. These mutations (e.g.,
L100I, G190S/A, and Y181C) alter the binding site of RT to NNRTIs which consequently
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decreases the binding affinity and alters the overall structure of the complex [39]. Other
mutations (e.g., K103N) can act using a different mechanism such as the establishment
of a hydrogen bond at the entrance of the binding pocket. This helps to maintain the
pocket closed and limits NNRTI diffusion. Nevertheless, one of the biggest hurdles related
to the use of NNRTI is that the binding site in RT is approximately the same for all of
them, which means that a single mutation can lead to high-level drug resistance and cause
cross-resistance among all NNRTI [36,41].
Furthermore, the resistance to PI is associated with mutations in the protease gene and
subsequent replacement of amino acids within the protease enzyme (e.g., D30N, V32I, G48V,
V82A, and others) [36,41]. These modifications will reduce the binding affinity between the
catalytic binding site of the enzyme and the PI [36]. Other mutations in the enzyme flap
(e.g., I54M/L) and core (e.g., L76V and N88S) can also decrease PI susceptibility [40]. In
response to these mutations, the geometry of the catalytic site of the homodimer is enlarged
disabling the inhibitor to effectively bind to the gene and block cleavage [36].
The development of resistance in FI is related to mutations in gp41 codons 36–45 (e.g.,
G36DEV, V38EA, Q40H, N42T, and N43D), correspondent to the location where T-20 will
bind [36,38]. In the case of II, the occurrence of mutations (e.g., N155H, Q148R, Y143R,
and others) at Asp64 and Asp116 carboxylate residues (which coordinate an Mg2+ ion)
compromise the catalytic activity of the enzyme [41]. It is thought that the functional
group of IIs binds selectively to the enzyme complexes which further interferes with
strand transfer of viral and host DNA [41]. Finally, cell entry inhibitors such as maraviroc
(CCR5 inhibitor) may develop resistance via gp120 mutations, enabling HIV to bind the
CCR5-CCR5 inhibitor complex [40]. However, the most common mechanism of resistance
to CCR5 inhibitors is associated with an enhancement of CXCR4 tropic viruses that are
intrinsically insensitive to CCR5 inhibitors [40].
Besides the resistance mechanisms, prolonged treatment regimens often result in
poor adherence and careless patient intake, as well as treatments with high associated
costs [2,42,43]. In addition to this, any interruption in the therapeutic regimen results
in treatment failure and viral resistance. Moreover, drug associations can improve the
therapeutic effectiveness, but they may also have the opposite effect due to an increase in
deleterious drug-drug interactions. Prolonged use of ARV therapeutic regimens is also
often associated with toxic side effects (e.g., constipation/diarrhea, abdominal pain, nausea,
liver and metabolic disorders, kidney stones, anemia, fatigue, headache, fever, muscular
dystrophy, and peripheral neuropathy) that compromise the quality of life of patients [44].
Pharmacokinetic issues are another significant limitation of cART and single ARV
therapies. In either case, ARV demonstrates low and unpredictable bioavailability after
oral administration due to their poor gastrointestinal (GI) absorption, extensive first-pass
metabolism, and GI enzymatic degradation. The majority of ARV drugs are classified in
biopharmaceutical class system (BCS) II, III, or IV, which means they have low solubility
and permeability. For drugs given orally, solubility is required to confirm drug absorption
and clinical response. The speed and extent of oral drug diffusion through the mucus
layer, submucosa, and epithelial cell barriers into the blood or lymphatic circulation is
referred to as permeability. Low solubility and permeability thereby show that ARV drugs
are poorly absorbed in the body [45]. Even after absorption, most ARV present other
significant pharmacokinetic limitations, such as a short half-life that demands recurrent
dose administration in a fastidious dosage regimen, which contributes to poor patient
adherence [2,44,45]. Another pharmacokinetic issue is poor body distribution of ARV,
which prevents reaching certain target tissues that serve as viral reservoirs. High plasma
protein binding of ARV, for example, impairs drug permeation across the BBB [46]. The
central nervous system (CNS) is known as an anatomical viral reservoir, where HIV
survives in long-lived cells, such as microglia. As a result, viral eradication by ARV
drugs or cART becomes more difficult and newer and drug-resistant HIV strains develop.
Furthermore, some ARV drugs’ inability to enter the CNS further restricts eradication.
ARV drugs may also be expelled from CNS at the BBB level by efflux transporters like
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glycoprotein P (P-gp) [47]. Simultaneously, the inflammatory response induced by HIV
infection of the CNS causes permeability increase of the BBB and plays an important role
in neuropathogenesis [47,48].
Moreover, ARV fails to target lymphatic system cells (e.g., dendritic cells and macrophages)
involved in virus transmission to helper T lymphocytes (CD4+ T cells), resulting in post-
treatment infection relapse [49].
To address the limitations of cART and single ARV therapies, there is an urge to
develop innovative strategies, such as nanocarriers for ARV delivery. Among the vast
types of nanocarriers available, lipid-based nanocarriers can be one of the most attractive
drug carrier classes for ARVs. The ability of these systems to transport drugs of vary-
ing lipophilicity, as well as their widely accepted biocompatibility and biodegradability,
make them appealing for translation into clinical settings [50]. Additionally, as the oral
route is the preferred method of administration, lipid nanocarriers stimulate the secretion
of endogenous biliary lipids enhancing the GI absorptive capacity of the carried ARV
agents [51]. Consequently, bioavailability enhancement and better distribution over the
cellular and organ target viral sites are expected. Indeed, lipid nanocarriers can protect
ARV agents (single or on association) through their body path, reducing accumulation in
non-target tissues (reducing toxic side effects) and improving doses at viral reservoirs, as
well as, avoiding unwanted drug interactions between the multiple carried drugs. The
more specific and controlled delivery of ARV agents provided by lipid nanocarriers may
also enhance therapeutic efficiency by decreasing the need for frequent administration
regimens, which ultimately increases patient adherence. There is also the need to seek
out novel alternatives capable of overcoming the physiological barriers inherent to oral
ARV drug administration. Therefore, lipid nanocarriers are likewise advantageous to
explore different non-invasive routes like skin transdermal, intranasal, and topical vaginal
administration (for pre-exposure prophylaxis purposes) [19,52–55].
Nanocarriers for ARV drugs delivery in the CNS have also proved useful in circum-
venting the BBB because of their potential to enhance drug permeability. Nanocarriers
have a variety of properties that help them penetrate the BBB and deliver drugs to the
CNS, such as a high surface-to-volume ratio, a positive surface charge (to take advantage
of adsorptive mediated transport through the BBB), and a small and regulated size (less
than 200 nm) [47,56]. The charge and hydrophobicity of the nanocarriers’ surface impact
plasmatic protein adsorption, and therefore their absorption and/or rate of transcytosis.
Nanocarriers coated with specific surface stabilizers may be useful in achieving greater
drug levels in the brain when it comes to CNS administration. Polysorbate 80 is a nonionic
surfactant that has been shown to improve brain delivery in a variety of nanocarriers by
adsorbing different apolipoproteins once in the circulation, imitating lipoproteins in their
receptor-mediated transcytosis pathway into the CNS [47].
Given all of the mentioned advantages of nanocarriers for ARV delivery, the following
section will provide a more detailed view of the types of lipid nanocarriers and their
engineering properties to improve ARV therapy.
3. Lipid-Based Nanocarriers for Delivery of ARV Agents
Lipid-based nanocarriers are organic nanosystems that self-organize upon input of
energy into a supramolecular structure with the hydrophilic portions (anionic, cationic, or
zwitterionic) exposed to the surrounding aqueous solvent and the hydrophobic portions
(usually hydrocarbon chains) facing each other to reduce contact with aqueous solvent [50].
Self-assembly is a common manufacturing method of lipid-based nanocarriers that is
spontaneous but driven by an input of energy and the hydrophobic effect [50]. Lipid-based
nanocarriers’ definitions and main characteristics are presented in Table 2.
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Table 2. Lipid nanocarriers description, schematic representation, and main advantages and disadvantages for ARV delivery.
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• Aqueous phases in the core and
surroundings of synthetic v sicles formed by
self-assembly of lipid bilayers.
• Unilamellar (1 bilayer), oligolamellar (2–4
bilayers), and multilamellar (>4 bilayers)
classifications are based on the number of
lipid bil y rs.
• Small (100 nm), large (100–500 nm), and
gia t (>500nm) are the classifications based
on their size.
• Ethosomes are phospholipid-based vesicles
with high ethanol content (20–45%).
• Biocompatible and biodegradable.
• Administration routes are limited (mainly
intranasal and intravenous).
• Production processes are difficult to scale.
• Liposomes in their natural state are quickly
absorbed by t reticuloendo helial system nd
cleared from circula ion. This property has been
used to deliver ARVs to macrophages.
• The tr nsdermal delivery of ARV is achieve by
t e incorporation of edge activators (e.g.,
surfactants, onoo ein forming transferosomes)
or ethanol (f rming ethosomes) in the lipid
bilayer.
• The protection f sensitive t erapeutics can be
achieved by using antioxidant agents in their
composition (e.g., α-tocopherol, forming
tocosome).
• Can encapsulate hydrophilic, hydrophobic, or
amphiphilic drugs.
• Limited hydrophilic drug-loading capacity.
• Low long-term physical and biological stability,
which hinders their use for long-term drug
delivery.
[19,53,57,58]
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Table 2. Cont.




















































• ighly stable structures organized in curved
bicontinuous lipid bilayers forming soft 3D
honeycomb-like structures.
• Composed by a continuous periodic bilayer
and two non-connected water channels.
• Main components: glyceryl
monooleate/monool i (GMO) and
phytantriol.
• Incapability to modulate inner pore and channel
sizes.
• Difficult loading of large molecules and difficult
scale-up processes.
• Biocompatible and bioadhesive.
• Increase drug olubility and bioav ilability
through a variety of routes, inclu ing intranasal
delivery to the brain and transdermal delivery.
• More stable than liposomes.
• High degree of encapsulation efficiency.
[59–63]
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• Colloidal self-assembled dispersions with a
hydrophobic matrix and a su factant layer
that facilitat s di p rsion in water. At body
and ro m t pe atures, lipid n nop rticles
are solid.
• So d lipid nanoparticles (SLN) are lipid
nanoparticles wit hydrophobic trices
made up of solid lipids.
• Nanostructured lipid carriers (NLC) have
lipid matrices with solid lipids and liquid
lipids (oils).
• Ease manufacturing and scale-up
• Low-cost and recognized as safe (GRAS)
excipients, and biocompatibility.
• reater drug stabil ty and better control over
drug-rel as kinetics than liposomes, cubosomes,
and nanoemulsions.
•
ent ap a greater amount of lipophilic drugs, but
are inadequate for encapsulating hydrophilic and
amphiphilic drugs.
• Good blood stability.
• Receptor-mediated transcytosis allows lipid
nanoparticles to cross the BBB (targeting
low-density lipoproteins receptors).
[7,64,65]
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Table 2. Cont.





























































































































• Colloidal systems ma e of immiscible liquid
p ases, categorized in water-in-oil (w/o) or
oil-in-water (o/w), according to the phase
dispersed in the other phase (continuous
phase) and stabilized by surfactants.
• Microemulsions are thermo-dynamically
stable dispersions that can be generated with
low external energy. The droplet sizes of the
dispersed phase are < 1000 m, typically
range between 10 and 200 nm, resulting in
optically clear dispersion.
• Nanoemulsions ar thermo-dynamically
unstabl and r quire high external energy to
be produced. Th ispersed phase droplets
are < 500 nm typically 100 n . Over time,
nanoemulsions are more prone to instability.
• Self-emulsifying drug delivery systems
(SEDDS) are emulsions that, when gently
agitated, form fine oil-in-water droplets
without the need for a dissolution process.
These include self-micro emulsifying
delivery systems (SMEDDS) with droplet
sizes < 50 nm; self-nanoemulsifying drug
delivery systems (SNEDDS) with droplet
sizes of 20 to 200 nm; and solid
self-nanoemulsifying oily formulations
(S-SNEOF) where the drug is precipitated as
a result of the evaporati n of the co-solvent.
• Increase drug oral bioavailability as their droplets
preserve the drug from gastrointestinal
degradation and can be dispersed quickly in
blood and lymph (thereby avoiding the first-pass
metabolism), but are also administrated by other
routes: topical, and intravenous.
• Composed by GRAS lipids. However, to stabilize
the droplets, high concentrati ns of surfactants
re used, and thus their toxicity and
biocompatibility may be compromised.
• Easy to a fact r s l , lt t
p oduction methods can be exp nsiv .
• In co parison to liposo es are ore stable a
provide higher encapsulation efficiency than
lipophilic drugs.
• SNEDDS have higher physicochemical stability
than classical nanoemulsions.
• SNEOFs promote lymphatic absorption by
inhibiting first-pa s metabolism and
P-glycoprotein (P-gp) efflux, resulting in the
complete eradication of HIV in lymphatic
reservoirs.
[29,66]
A breviatio s: , antiretroviral; BB , blood-brain barrier; GI, gastrointestinal; GMO, glyceryl monooleate/m nool in; GRAS, generally recognized as safe; HIV, hum n immunodeficiency virus; NLC,
nanostruct red lipid carriers; o/w, oil-in-water; P-gp, P-glycoprotein; SEDDS, self-emulsifying drug delivery systems; SLN, solid lipid nanoparticles; SMEDDS, self-micro emulsifying deliv ry systems; NEDDS,
self-nanoemulsifying drug delivery systems; S-SNEOF, solid self-nanoemulsifying oily formulations; w/o, water-in-oil.
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Because of their nanoscale dimensions and adjustable surface properties, lipid-based
nanocarriers are frequently advantageous for delivering antivirals to affected areas [67].
Several earlier studies have proven the potential of lipid-based nanocarriers to encapsulate
and transport ARV. Representative examples are presented in Tables 3–5, highlighting
the structure, composition, and physicochemical properties of nanocarriers, as well as
the main challenges that were overcome by their use. Generally speaking, we may say
that appropriate nanocarriers for drug delivery may be able to compensate for ARD
drugs’ limitations and increase their pharmacological efficacy. One goal shared by all
studies is the development of nanocarriers to reduce the side effects of ARD drugs. The
concentration of AZT inside red blood cells, for example, caused hematopoietic toxicity.
Liposomes containing AZT decreased blood cell absorption, overcoming AZT’s negative
hematopoietic effects [57,68] (Table 3). Liposomes have also been shown to reduce ddI
systemic exposure [69] while providing the same therapeutic effect as free NVP at lower
doses (and thus with less toxicity) (Table 3) [70]. Furthermore, NLC containing EFV had
lower toxicity when compared to the free drug (Table 5) [54]. Lipid nanocarriers can also
be designed to improve drug bioavailability and prolong release thereby extending the
dose interval. Because of their solid lipid matrix, SLN was the most capable of providing
sustained release of the ARV encapsulated, reducing the frequency of administration.
For example, the encapsulation in SLN of LPV, d4T, SQV, EFV, DRV, and AZT [64,71–76]
provided a sustained release of this ARV even in the case of more hydrophilic drugs such
as AZT (logP = 0.5) and d4T (logP = 0.72). All PI ARV (Figure 6) are cytochrome P450
3A substrates, which explains why most of them have poor pharmacokinetic features,
such as extensive pre-systemic first-pass metabolism and short elimination half-lives [77].
There is also evidence that PI intracellular concentrations are influenced by P-gp and/or
the activity of other efflux transporters. Moreover, some other ARV drugs inhibitors
of RT have also documented short plasma half-lives (e.g., d4T, AZT, ddI) [78] which
reduce their target tissue distribution. The ability of lipid nanocarriers to mediate the ARV
distribution and increase their half-lives is therefore an important advantage. For example,
liposomes have been documented as capable to increase half-lives of d4T, AZT, ddI, and
RTV [13–16,20,79,80] (Table 3). Finally, many ARTs have a limited bioavailability in the
brain, but the ability of lipid nanocarriers to mediate the brain delivery of ARVs has been
widely documented, either for liposomes that potentially improve brain accumulation of
AZT [81], or for SLN used for improving brain bioavailability of ATV, SQV, EFV, NVP
and DRV [64,65,82–85], or NLC used as carriers of LPV, ATV, ETR [83,86,87] and NE
improving brain accumulation of SQV and IDV [88–90]. From these studies it is worthwhile
highlighting the SLN developed for EFV delivery that attained 150 folds more brain
targeting delivery than the free drug [84]; the NLC for ATV delivery that attained 2.75 folds
higher Cmax at the brain and 4 folds higher brain bioavailability [86] and NE as a carrier of
IDV that assured specific brain accumulation of the drug [89] (Tables 3–5).
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logP = −1.35 48.3 ± 2.6 N.D. N.D. 39,600 ± 11,900




1991/92 DPPC:DMPG (10:1) orDSPC:DMPG (10:1)
AZT a
logP = 0.05 N.D.
LP w/DPPC: 9.35 ±
0.45







1994 DSPC:DSPG (10:3) ddI
a
logP = −1.24 85 ± 15 21 ± 1 N.D. 180 ± 20
↑ bioavailability
↓ systemic exposure
↓ effective fighting the
virus compared to free
ddI
[69] *,**
1995 DPPC:DCP:Chol (4:1:5) ddClogP = −1.35 N.D. 35 N.D. 300

























logP = −0.72 35 to 50 N.D.
+, − and neutral




















logP = 2.9 11 ± 4 N.D. N.D. 100 to 120
↑ [IDV] to lymphoid
tissues [94] *
2003 EPC:Chol (3:1) IDV
g
logP = 2.9
97.5 ± 2.5 at pH
7.4
≈ 20 at pH 5.5
19.5 ± 0.5 at pH 7.4
≈4 at pH 5.5 N.D. 69 ± 7
↑ CD4+ T cells
↓ viral load in lymph
nodes and plasma
[95] *
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RES and brain [81] *
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↑ hepatic cellular d4T
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[14] *,**,***
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Note: intended for oral
administration
ddI
logP = −1.24 N.D. N.D. N.D. 1160 ± 129 ↑ bioavailability [97] **





E.E. (%) D.L. (%) ζ-Potential (mV) Size (nm)
2007 PC:POPG (3:1)
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logP = 2.9 SQV
logP = 3.8
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↑ cellular uptake in
lymphoid cells
↑ biodistribution



































Man-LP: 127 ± 1.2











PI1 N.D. N.D. N.D. N.D.












E.E. (%) D.L. (%) ζ-Potential (mV) Size (nm)
2010 EPC:Chol (9:1) NVPlogP = 2.5 78.1 7.81 N.D. <200
↑ E.E.






99 8.83 −0.8 ± 0.5 187 to 208
↑ ddI blood half-life
(3-fold)
↑ accumulation as





2011 DPPC:EDPPC (1:1) SFVlogP = −19.5 N.D. N.D. N.D. N.D.
Strong affinity of SFV
for DPPC:EDPPC












logP = −1.6 3.46 to 65.26 N.D. +4.79 to +17.13 36.13 to 114.9
The composition had
a significant impact on
TFV release
















E.E. (%) D.L. (%) ζ-Potential (mV) Size (nm)
2012 EPC:DSPE-PEG SQVlogP = 3.8 32.2 ± 2.9 N.D. −35.50 ± 1.66 176.6 ± 6.8
↓ cytotoxicity with




































and high Chol content
In the 2nd stage,
significant differences
in TFV release rate











(1:1:0) to 70.8 ±
2.55 (2:1:1)
0.39 ± 0.087 (1:1:0) to
17.71 ± 1.87 (2:1:1)
−3.43 (1:1:0) to
+93.5 (5:5:1)
46.6 (1:1:0) to 2,200
(2:1:1)
↑ permeation of TFV

























RTV release to 34 h
↑ half-life of RTV for
stealth LP




























2017 HSPC:Chol (7:3) LPV
b
logP = 5.94
90.47 ± 0.32 N.D. −24.8 ± 0.21 659.7 ± 23.1
↑ LPV release at 60
min (95% for LPV
loaded proliposomes













logP = 2.5 and
SQV logP = 3.8
NVP: 44 ± 2
SQV: 44 ± 1 N.D. −29 ± 2 160 ± 2





released in the early

























Plain LP: 126.6 ± 6.2
Biotin-LP: 149.8 ±
6.8














ATV: 99 ± 8.2
RTV: 92 ± 7.1
TFV: 10 ± 0.8
N.D. N.D. 6 to 62













84 1 Zwitterio-nic 134 ± 13





























Size was affected by
PPIX











E.E. (%) D.L. (%) ζ-Potential (mV) Size (nm)
Ethosomes
2007 SPC w/ethanol 3TC
c
logP = −1.4 57.2 ± 4.1 N.D. −8.2 ± 1.5 102 ± 13
↑ cellular uptake










61 ± 4.6 (219:9:1)
to






























↑ particle size with

















































N.D. N.D. ↓ with increasingChol
↑ TDF release for LP
without Chol
↑ transmigration
across an in vitro BBB
model by magnetic
targeting








LP + magnetic AZTTP
NP
AZTTP 54.5 ± 6 N.D. N.D. ∼150 nm
↑ permeability (3-fold)
for magnetic AZTTP
LP than free AZTTP


























100 4 (FTC) and 2.8 (TDF) LP−0.67 ± 0.01 211 ± 24







for 5 days of oral
TDF/FTC
Drug concentrations
in vaginal fluids were
fairly sustained up to






Notes: a intravenous injection; b oral administration; c transdermal administration; d intranasal administration; e intraventricular administration; g subcutaneous injection; h vaginal administration; N.D. no data *
in vivo studies performed; ** in vitro studies performed; *** ex vivo studies performed. Abbreviations: 3TC, lamivudine; ARV, antiretroviral; ATV, atazanavir; Au, gold; AZT, zidovudine; AZT-M, zidovudine
myristate; AZTTP, azidothymidine 5′-triphosphate; BBB, blood-brain barrier; CaSki, epidermoid cervical cancer cell line; Chol, cholesterol; CNS, central nervous system; CTAB, cetyltrimethylammonium
bromide; d4T, stavudine; DCP, dicetyl phosphate; ddC, zalcitabine; ddI, didanosine; DMEM, Dulbecco’s Modified Eagle’s Medium; D.L., drug loading; DLMA, inner uncoated liposomes; DMPC, 1,2-dimyristoyl-
sn-glycero-3-phosphocholine; DMPE, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine; DMPG, 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol); DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine;
DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DPPE-PEG2000, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene
glycol)-2000]; DPPG, 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol); DPTAP, 1,2-dipalmitoyl-3-trimethylammonium-propane (chloride salt); DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE,
1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; DSPG, 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol); EDPPC, cationic 1,2-dipalmitoylethyl-phosphatidylcholine; E.E., entrapment efficiency; EPC,
egg phosphatidylcholine; FTC, emtricitabine, Gal-DLMA, inner galactosylated liposomes; Gal-DMPE, galactosylated phosphatidylethanolamine; GMO, glyceryl monooleate; HEC-1-A, human endometrial
cancer-1; HIV, human immunodeficiency virus; HSPC, hydrogenated soy phosphatidylcholine; IDV, indinavir; logP, partition coefficient; LP, liposome; LPV, lopinavir; MAL, maleimide; Man, mannose; MCZ,
miconazole nitrate; MPEG 2000, mono methoxy PEG 2000; mPEG, methoxyl poly(ethylene glycol); MNP, magnetic nanoparticles; MPS, mononuclear phagocyte system; N.D., no data; NP, nanoparticles; NVP,
nevirapine; OPG, O-palmitoylgalactose; OPM, O-palmitoylmannose; PBS, phosphate buffered saline; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEG, polyethylene glycol; PEG-8-L, octaoxyehtylene
laurate ester; PLPC, 1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPG,
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol); PPIX, protoporphyrin IX; ProddINP, glycerolipidic prodrug of ddI; PS, phosphatidylserine; PVA, poly(vinyl alcohol); RES, reticuloendothelial system;
RTV, ritonavir; SA, stearylamine; SFV, sifuvirtide; SM, sphingomyelin; SPC, soy phosphatidylcholine; SQV, saquinavir; T20, enfuvirtide; TDF, tenofovir disoproxil fumarate; TFV, tenofovir; VE, α-tocopherol.
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PE-PEG SLN: 182 ± 44
↓ release rate in
SLN-PE-PEG
↑ bioavailability


















↑ uptake in hepatocytes
↑ controlled release
(12–15% in 24 h)
[76] *,**
2008
Lipid phase: stearic acid
Aqueous phase: Pluronic®
F68 (3%)










18.43 ± 0.70 167 ± 8.3
Burst ATV release of≈17%
by 1 h and gradual release
up to 40% by 24 h
↑ uptake and
accumulation of ATV
when delivered by SLN
(human brain endothelial
cell monolayer) compared





butter (wt of 8%)










SQV > DLV > d4T N.D. N.D.
142–308
↑ % Compritol® 888
ATO: ↑ d4T-SLN mean
size and ↓ DLV-SLN
and SQV-SLN mean size
↑ E.E. for d4T
Sustained drug release:
d4T > DLV > SQV
[74] **













>99 N.D. −26.5 ± 0.45 230.4 ± 5.6
Slow-release in both
media pH 6.8 and pH 1.2
↑ bioavailability and
targeting




Lipid phase: Softisan® 100
Aqueous phase: BSA and
PAA (negative moiety)







logP = −1.6 8.3 ± 0.7 0.083 −51.07 ± 4.44 153.66 ± 11.33
Non-cytotoxic (human





Lipid phase: Dynasan® 114









logP = −0.72 96 ± 4.42 N.D. −34.48 75 ± 1.22
↑ residence in splenic
tissues
↑ uptake by macrophages
compared to free drug
[119] *,***





E.E. (%) D.L. (%) ζ-Potential(mV) Size (nm)
2011
Lipid phase: Compritol®
888 ATO/steric acid (4%)
Aqueous phase: DODAB
(1.8%), Tween® 80 (1%),
lecithin (0.2%) and
1-butanol (0.5%)















↑ E.E. with SLN
↓ HBMECs viability with
NVP-SLN







wt fractions of palmitic acid in
Dynasan-palmitic acid




Tween® 80 and SDS (1%)
Note: wt fractions of
poloxamer 407 in
poloxamer 407-Tween® 80
were 0, 0.5, and 1, 0.1% (w/v)





logP = 3.8 ≈55 to 80 N.D. >−30 120 to 450
↑ BBB permeation
















86 N.D. −15.9 124.5±3.2





























SLN: 113 ± 0.2
PA-SLN: 163 ± 0.5







Compritol® 888 ATO (20%)
Aqueous phase: Lipoid® S




85.6 39.4 −35.55 168.92 ± 31.2
Prolonged and biphasic in
PBS pH 6.8
↑ bioavailability





Lipid phase: stearic acid
Aqueous phase: PVA















SLN: 222 to 227
SLN-AV: 402 to 434
↑ solubility






Lipid phase: GC and GMS
(1.5 g)













SLN: −22 ± 2
SLN: 210
Freeze-dried SLN: 270
Sustained release of DRV
until 12 h
Apparent permeability
across rat intestine: 24 ×
10−6 (cm/s) at 37 ◦C and
5.6 × 10−6 (cm/s) at 4 ◦C
Endocytic uptake
[73] **,***












64.9 N.D. −21.2 108.3
Burst release followed by
a prolonged release
↑ [EFV] in brain
↑ brain targeting
efficiency (more 150 times)
and better absorption of












logP = 3.9 21.4−53.3 N.D.
−39.35 ± 1.2 to
−50.80 ± 4.8 178 to 254
↑ E.E. and mean size




















70 to 1100 (average
particle size ~212 nm)
Biphasic release profile
with an initial burst
release





















logP = 5.94 69.78 N.D. −17.7 ± 0.54 48.86 ± 4.6
↑ sustained LPV release
from SLN based HG
(71.197 ± 0.006% after 12
h) compared to plain HG
of the drug released
(98.406 ± 0.007% after 4 h)
SLN based HG resulted in
the highest Cmax (20.3127
± 6056 µg/mL) compared
to plain HG (8.0655 ±
1.6369 µg/mL) and oral





castor oil (castor wax)
Aqueous phase: sodium
oleate (3.5%)




















D-SLN: 189.45 ± 2.10
Pept-D-SLN
195.11 ± 1.53
↑ DRV release in SLN
compared to a plain drug
suspension
↑ permeability in Caco-2
cells (4-fold) than free
drug
↑ uptake in HIV host cells
(molt-4 cells were taken as
a model containing CD4
receptors) as compared to
non-CD4 receptor-bearing
Caco-2 cells
↑ bioavailability than free
DRV:
↑ uptake in various
organs (also in HIV
reservoirs like spleen and
brain) with
Pept-DRV-SLN
↑ binding with the HIV
host cells
[82] *,**





E.E. (%) D.L. (%) ζ-Potential(mV) Size (nm)
NLC
2011




(1.8%), Tween® 80 (1%),
lecithin (0.2%) and
1-butanol (0.5%)






























3TC-NLC: 34 ± 1














Unloaded-NLC: 229 ± 2
3TC-NLC: 218 ± 4
Unloaded MLN: 426 ± 9
3TC-MLN: 450 ± 10
Sustained and controlled
3TC release under gastric
and plasma-simulated













Tween® 80 (158 mg)






















AZT-NLC: 266 ± 4
M-AZT-NLC: 113 ± 3

















83.6 N.D. + 21.2 196.6
↑ bioavailability
↑ [LPV] in the brain





Lipid phase: Precirol® ATO
5:LauroglycolTM
90 (70:30)
Cremophor® RH 40 (3%)
ATV b
logP = 4.5
71.09 ± 5.84 8.12 ± 2.7 −11.7 ± 0.47 227.6 ± 5.4
Fast release (60%) in the
initial 2 h, followed by
sustained release
↑ permeation of ATV
(2.36-fold) across the rat
intestine as compared to
the free drug
2.75-fold greater Cmax in
the brain and a 4-fold
improvement in brain
bioavailability as




(71.5%): Capmul® PG 8
(28.5%)
Aqueous phase:






composition + CTAB (1%





















Plain NLC: 114.53 ±
5.63







Uptake of cationic NLC
by THP-1 macrophages
↑ retention/sustained




















Aqueous phase: Lutrol® F
127 (1%)
ETR a
logP = 4.5 >90 5 to 10 −20 ± 2.3 351.7 ± 3.36




compared to the free drug
↑ [ETR] several-fold in the
liver, ovary, lymph node,











Tween® 80, sodium cholate;
PEG 6000 (1%), propylene
glycol (1%), BHT (0.4%)
Note: Surfactant mixture
[(Tween® 80: Span® 80
(70:30)]: 5%
DTG
logP = 2.2 88.09 N.D. −16.6 123.1




(≈94.02%) as compared to
plain drug suspension
(only 55.62%) after 8 h
[125] **,***
2014
Lipid phase: Precirol® ATO
15 (10%) and Miglyol® 812
(1%)
Aqueous phase: Tween®
80 (1%) and poloxamer 188
(1 or 0.5%)






−36 ± 6 to −22
± 4
Dex-Prot NLC:
−0.5 ± 4 to +12
± 4
Uncoated NLC: 152 ± 1
to 936 ± 1
Dex-Prot NLC: 244 ± 1
to 1326 ± 1
↑ permeability (up to
9-fold) with Dex–Prot











E.E. (%) D.L. (%) ζ-Potential(mV) Size (nm)
2017
Lipid phase: Precirol® ATO





95.78 ± 0.42 N.D. −18.7 ± 1.0 161 ± 2.8
EFV release of 92.45%
after 24 h
The therapeutic





compared to free EFV
[54] *,**
Notes: a intravenous injection; b oral administration; c transdermal administration; d intranasal administration; f intraperitoneal administration; N.D. no data * in vivo studies performed; ** in vitro studies
performed; *** ex vivo studies performed. Abbreviations: 3TC, lamivudine; ARV, antiretroviral; ATV, atazanavir; AUC, area under the curve; AV, aloe vera; AZT, zidovudine; BBB, blood-brain barrier; BHT,
butylated hydroxy toluene; BSA, bovine serum albumin; Capmul® MCM EP, glycerol monocaprylocaprate; Capmul® PG 8, propylene glycol monocaprylate; CapryolTM 90, propylene glycol monocaprylate;
Captex® P 500, triglycerides and esters prepared from fractionated vegetable oil sources and fatty acids from coconuts and palm kernel oils; CC50, concentration at which 50% cells are viable; Chol, cholesterol;
Cmax, maximum concentration; CNS, central nervous system; Compritol® 888 ATO, glycerol dibehenate; Cremophor® RH 40, polyoxyl 40 hydrogenated castor oil; CTAB, cetyltrimethylammonium bromide; d4T,
stavudine; Dex–Prot, dextran–protamine; D.L., drug loading; DLV, delavirdine; DMPG, 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol); DODAB, dioctadecyl dimethylammonium bromide; DPPC,
1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DRV, darunavir; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; DTG, dolutegravir sodium; Dynasan® 114, trimyristin; Dynasan® 118, glyceryl
tristearate; E.E., entrapment efficiency; EFV, efavirenz; ETR, etravirine; GC, glyceryl caprylate; Gelucire® 44/14, lauroyl polyoxyl-32 glycerides; Gelucire® 50/13, stearoyl polyoxyl-32 glycerides; GMS, glyceryl
monostearate; HBMECs, human brain microvascular endothelial cells; HG, hydrogel; HSA, human serum albumin; HSPC, hydrogenated soy phosphatidylcholine; Labrasol®, caprylocaproyl polyoxyl-8
glycerides; LauroglycolTM, 90 propylene glycol monolaurate; Lipoid® S 75, fat free soybean phospholipids with 70% PC; LPV, lopinavir; mAb, 83-14 monoclonal antibody; Miglyol® 812, medium-chain
triglycerides; MLN, multiple lipid nanoparticles; MonosteolTM, palmitate/stearate of propylene glycol; MYS-25, polyethylene glycol 25 stearate; N.D., no data; NLC, nanostructured lipid carrier; NVP, nevirapine;
PA, phenylalanine; PAA, poly(acrylic acid); PC, phosphatidylcholine; PE-PEG2000, dipalmitoylphosphatidylethanolamine-N-[poly(ethylene glycol)2000]; PEG, polyethylene glycol; Pept-DRV-SLN, peptide
grafted-darunavir loaded SLN; PGDS, polyglyceryl-6-distearate; PLL, poly(L-lysine hydrochloride; Plurol® Oleique CC 497, polyglyceryl-3 dioleate; Precirol® ATO 15, glyceryl palmitostearate; PVA, poly vinyl
alcohol; RTV, ritonavir; SA, stearylamine; SDS, sodium dodecyl sulfate; SL, soy lecithin; SLN, solid lipid nanoparticle; Softisan® 100, hydrogenated coco-glycerides; Solutol® HS15, polyoxyl 15 hydroxystearate;
SQV, saquinavir; TFV, tenofovir; w/w- weight/weight; wt—weight.
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logP = 1.89 99.42 N.D. N.D. 40.68
↑ solubilityGreater intestinal
permeability than the free drug ↑






(30%); Oleic Plurol® (10%)
AZT c
logP = 0.05 N.D. N.D. N.D. N.D.
↑ AZT permeated (≈2-fold) as
compared to control—HGNo
apparent skin irritation; little





Lipid phase: Flax-seed oil
or safflower oil (1 mL)
Aqueous phase: EPC (3%)
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Subsequently, a detailed and critical analysis of studies selected from Tables 3–5 is
presented in Section 3.1 with a focus on the route of administration and Section 3.2 that
focused on targeting strategies.
3.1. Tuning the Physicochemical Properties of Lipid-Based Nanocarriers to Overcome Biological
Barriers
According to the administration route (Figure 7) and to achieve particularly in vivo
performance and clinical applications, specific aspects of nanocarriers such as composition,

































Figure 7. Potential ART (antiretroviral therapy) administration routes (left side in blue). The nanocarrier cartoon marks all
possible routes of dministration for lipid-b sed nanosy ems. Classical ART formu ations for ther py or p e-exposure
pro hylaxis (PrEP) are li ited to ral and parenteral routes. Biological barriers to ART dministration (right side in red).
Several studies have been conducted for parenteral administration of ARV (e.g., sub-
cutaneous, in rav nous). In this case, it is c itical to extend the circulatory residence of
the anocarriers to en ure adequate ime for distribution to the t rget tissu s. Avoid-
ing psoniza ion of s rum proteins (e.g., human serum albumin, HSA) by c ntrolling
the size (<250 nm), charge (avoid positively charged nanocarriers), and surface coating
with hydrop ilic polymers (e.g., polyethyle e glycol, PEG) are some str egies for ex-
tending circulation time. These criteria were met by Gagné et al. and Sudhakar et al.
(lipos mes) [80,94], by Hei ti et al. (SLN) [18] and Pokharkar et l. (NLC) [54]. Aside
from extending th circulation time of nanoc rriers, it is also critical to us targeting strate-
gies that can deliver ARV drugs to sites of latent HIV reservoirs such as lymph nodes,
the spleen, and the gut mucosa, where HIV-target cells such as memory CD4+ T cells,
macrophages, microglia, and astrocytes in the CNS are prevalent [137]. Some of these tar-
geting strategies include: (i) surface functionalization of nanocarriers with sugar molecules
like mannose [13,99] or galactose [14,15,96] that are recognized by lectin receptors found on
the surface of cells from the mononuclear phagocyte system (MPS); (ii) coating of nanocar-
riers with hydrophilic molecules (e.g., amino acids, glucose) to facilitate BBB permeation
by carrier-mediated transcytosis [55]; (iii) engineering of the lipid matrix of the nanocar-
riers (SLN, NLC, nanoemulsions) in order to mimic low-density lipoproteins (LDL) that
are recognized by LDL receptors, thus facilitating BBB permeation by receptor-mediated
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transcytosis [54,55,64,65,85,87,89,90,120]; (iv) functionalization with ligands (e.g., HSA and
monoclonal antibody (mAb)) that enhance BBB permeation by receptor-mediated transcy-
tosis [64,120]; (v) inhibition of P-gp, which increases brain-specific accumulation [89]; and
(vi) magnetic aided transport across BBB [115] and to MPS cells [116].
Oral administration is one of the preferred routes of administration due to its conve-
nience that assures better adherence to the therapeutic regimens. However, this route of
administration presents several limitations such as the variable absorption of the drugs,
drug degradation by enzymes and acidic pH in the stomach, and first-pass metabolism
effect. The physicochemical properties of drugs determine their absorption through the
GI tract, namely their lipophilicity, which can be assessed by the logP. Typically, only
drugs with logP values between 1 and 3 have favorable oral absorption profiles [138].
Most ARV drugs are outside this range (Tables 3–5), being either extremely hydrophilic
(e.g., ddI [97] and AZT [121]) or highly lipophilic (e.g., LPV [66,71,83,109], RTV [110],
EFV [16,75,129], SQV [90,126], EFZ [131] and ATV [86]). Therefore, lipid-based nanocarri-
ers may help ARV drugs achieving a balanced lipophilic/hydrophilic nature. Additionally,
lipid-based nanocarriers can be site-specific delivery systems by modifying their surface
with ligands that are recognized at target tissues. For example, following oral adminis-
tration, biotinylated liposomes of insulin were observed to permeate the GI tract via a
facilitated absorption mechanism [139]. Based on this study, liposomes were coated with
biotin (biotinylated proliposomes) to improve uptake of RTV into the intestinal lymphatic
tissues [110]. Another example is the SLN grafting with a peptide that is specific for CD4+
receptors present on T cells, which improved specific DRV uptake by HIV host cells [82].
The nature of the components of nanocarriers also influences their functional perfor-
mance when administered via a specific route. In the case of the oral route, the components
of lipid-based nanocarriers induce the production of endogenous biliary lipids, which form
colloidal structures in the presence of bile salts and significantly improve the solubilization
and absorption capacity of ARVs in the small intestine [51]. Furthermore, the inclusion of
penetration enhancers (e.g., Transcutol® [66,127,129,131] and biliary salts (deoxycholic acid,
sodium cholate) [90,125]) in the lipid matrix composition also improves the oral delivery
of ARVs agents.
Transdermal administration, as opposed to oral administration, avoids the first-pass
metabolism effect of drugs. As a result, a lower quantity of drugs can be administered
efficiently by the transdermal route with reduced toxicity to achieve the same bioavailability
as the oral route [72,113]. The fact that not all drugs can be delivered transdermally
is one of the major drawbacks of this method. Drugs with a high molecular weight
(>500 Da) cannot penetrate the stratum corneum [11]. In the pharmaceutical field, lipid-
based nanocarriers are the most used for dermal/transdermal drug delivery. To improve
skin permeation and efficiency, the composition of liposomes is changed to create new
classes of lipid vesicles known as transferosomes, niosomes, ethosomes, cubosomes, and
tocosomes. Jain et al. developed ethosomes that, due to the high amounts of ethanol, aid in
breaking the stratum corneum and have higher elasticity, which contributes to improved
3TC skin permeation [112]. Chettupalli et al. produced cubosomes that improved ATV
transdermal permeation due to the bioadhesive and permeation enhancer effect of their
components [113]. SLN and nanoemulsions have also proved effective for the transdermal
delivery of LPV [72] and AZT [128] respectively.
The vaginal administration is a promising route that allows self-administration of
ARV drugs and permits achieving both local and systemic effects. In the case of local ad-
ministration, the vaginal route avoids systemic exposure reducing side effects. If systemic
administration is intended then drugs should have hydrophobic properties and low molec-
ular weight [140,141]. The vaginal route may also be advantageous for drugs that undergo
extensive metabolism, as it avoids the hepatic first-pass effect and allows for a reduction in
the doses of drugs administered [141]. However, the vaginal route has been exclusively
considered for topical pre-exposure prophylaxis (PrEP), as a preventative approach. Due
to the unique characteristics of this mucosal site, administering ARV drugs via the vaginal
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route is a huge challenge because a fine-tuning of mucoadhesiveness/muco-penetration
is required to ensure good distribution along the cervicovaginal lumen. In this regard,
lipid nanocarriers can be used to improve ARV permeation into the vaginal mucosa, but
there are some requirements in terms of size (>100, preferentially 200–500 nm) and surface
charge (positively charged nanocarriers are mucoadhesive and hinder diffusion, whereas
PEGylation promotes mucosal permeation) [142]. These requirements were considered
in an in vitro study in which liposomal hydrogels were developed for the delivery of two
ARV drugs with different lipophilicities [52]. As such, the hydrogel (hydrophilic) was
used as a carrier for the hydrophilic drug FTC, while the liposomes were used as carriers
for the more lipophilic drug TDF. The size and zwitterionic charge of the liposomes, as
well as the hydrophilic nature of the gel, imply that there are fewer interactions with
mucin from the mucosa, which may translate to higher drug diffusion [52]. SLN was
also strategically developed to improve TFV uptake by virus-infected cells via vaginal
administration [118]. TFV-loaded SLN were functionalized with a combination of peptide
(PLL), to enhance intracellular uptake of the drug, and heparin, which can direct nanocar-
riers to killer lectin-like receptors of natural killer (NK) cells, resulting in direct killing of
virus-infected cells [118]. Moreover, SLN possessed an adequate size and high density
of negative surface charge that creates a hydrophilic surface that facilitates diffusion and
minimizes entrapment into mucus [118]. In another study, a hybrid system composed
of polymeric nanofibers containing liposomes loaded with FTC and TDF provided rapid
onset of local ARV levels in mice after a single vaginal administration compared to five
days of continuous daily use of oral TDF/FTC [117]. These results may be also translatable
into a fairly wide protection time window in humans [117].
Intranasal administration has recently been investigated as a potential alternative to
intravenous and other systemic administration routes for providing direct access to the
brain via axonal transport along the olfactory nerve [50]. This administration route has the
advantage of increased bioavailability due to the absence of first-pass liver metabolism and
subsequent rapid absorption, resulting in a rapid therapeutic effect [50]. The disadvantages
of this route are related to the limited amounts of drugs that can be delivered into the
brain and to the mucociliary clearance mechanism that can remove toxic substances, drugs,
nanocarriers, and microorganisms caught in the mucus layer [50]. To overcome the mucocil-
iary clearance mechanism, the lipid matrix composition, and the surface chemistry of the
nanocarriers have been explored for ARV delivery. Tuning the surface coating is important
to guarantee enough mucoadhesion to avoid the rapid removal of lipid nanocarriers from
the nasal mucosa [50]. On the other hand, it is also necessary to impart the nanocarrier sur-
face with mucopenetrating properties to improve diffusion from the nose to the brain [50].
For example, Pokharkar et al. and Mahajan et al. used PEG coatings as amucopenetrating
strategy for intranasal brain delivery of EFV [54] and SQVM [88], respectively. Other ARV
drugs (SQV and EFV) benefited from nanocarriers composed of lipids with mucoadhesive
properties (e.g., monoolein) [114] or fatty acids with mucopenetration properties [54,84].
The ability of nanocarriers composed of fatty acids to be flexible and pass through the
opening of the olfactory epithelium has been attributed to the surfactant nature of fatty
acids, which may disrupt the nasal membrane [50].
3.2. Targeting Anatomical and Cellular Reservoirs
As previously mentioned, lipid nanocarriers’ surfaces can be functionalized to im-
prove their targeting selectivity [143]. The reticuloendothelial system contains galactose
and lectin receptors and thus galactosylated [14,15,96] and mannosylated [13,99] liposomes
target these receptors and have been utilized to deliver AZT, ddI, and d4T to the reticuloen-
dothelial system. Functionalization of lipid nanocarriers with mAb, such as anti-HLA-DR
that target follicular dendritic cells, B cells, and macrophages that express the HLA-DR is
another strategy to achieve targeting specificity. For example, immunoliposomes function-
alized with mAb resulted in increased IDV accumulation in mouse lymph nodes, with an
area-under-the-curve that was 126-fold more than that of the free drug [94]. Liposomes
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can also be coated with recombinant soluble CD4 molecules [144,145], the Fab’ fragment
of monoclonal antibody F105 [100], or the Fab’ fragment of anti-HLA-DR antibody [146],
which all target gp120 on HIV-infected cells [143,145]. Besides sugars and mAb, PEG is also
a surface targeting moiety that increases lipid nanocarriers at the lymph nodes [143,147].
In the case of BBB targeting the lipid-based nanocarriers have the potential to reduce
efflux transporter binding by increasing brain accumulation. When ATV was encapsulated
in solid lipid nanoparticles, its accumulation in a human brain microvessel endothelial cell
line (hCMEC/D3) was greatly increased, indicating that this is a promising strategy for
delivering ATV across the BBB [65]. When SQV was given by oil-in-water nanoemulsions
synthesized with essential polyunsaturated fatty acid-rich oils, the maximal concentration
and area-under-the-curve values in the brain were five- and threefold higher than the
aqueous suspension [90]. Besides the lipid nanocarrier composition, it is advisable their
surface functionalization with targeting ligands (e.g., Transferrin, and apolipoproteins) [47]
that are recognized by BBB receptors and favor BBB transcytosis (examples of additional
targeting ligands for BBB crossing can be consulted in [56]). Finally, one of the most
tested cell-penetrating peptides is the HIV-1 Tat peptide. Certain sections of this peptide,
known as protein-transduction domains, can help it migrate through biological membranes.
The fusing of -galactosidase to the Tat peptide is required for BBB permeability, which
is independent of transporters and receptor-mediated endocytosis [47]. Hence surface
functionalization of lipid nanocarriers with Tat peptide can be an effective strategy for BBB
crossing [47]. Glutathione is another peptide that is frequently utilized to achieve brain
targeting. This endogenous tripeptide has antioxidant properties and plays a key function
in intracellular metabolite detoxification. The ability of glutathione to increase ARV drugs
delivery to the brain via liposomes has been demonstrated [47].
4. Biotechnological Advances in ARV Delivery
In the previous sections we have presented the classical therapy approach of HIV
infections/AIDS based on the use of ARV drugs. Although cART can reduce HIV replica-
tion and postpone the onset of HIV infection/AIDS, viral mutagenesis is common and can
lead to ineffective ARV therapy. New prospects of HIV treatment include biotechnological
approaches combining pharmacological compounds and, in particular, genetic therapy,
which uses RNA interference (RNAi). RNAi mechanisms are used in the context of gene
therapy to modulate/silence the expression of genes involved in disease. Small interfering
RNA (siRNA) operate within the RNAi pathway and have become the focus of recent ther-
apeutic applications. Double- and long-stranded RNAs interact with a complex of proteins
in the cytoplasm of cells, which is then cut into small double-stranded RNAs (19–21 nu-
cleotides), known as siRNA, via Dicer enzymes. When siRNA enters the RNA-induced
silencing complex (RISC complex), its double strands are separated into two single strands
(antisense and sense), the antisense strand (guide) binds to a messenger RNA (mRNA)
with a complementary sequence, and the mRNA target is degraded by non-RISC-complex
endonucleases, halting the production of the abnormally encoded protein or enzyme [148]
(Figure 8).
The high potential of this strategy in comparison to others stems from the fact that
when an appropriate siRNA is used, regular expression of any other gene implicated in
other diseases is possible. The significance of studies developed by Fire and Mello [149] to
discover RNAi cellular mechanisms was recognized with the Nobel Prize in Physiology or
Medicine in 2006 [150].
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Figure 8. echanis of siR A activity. RNA-induced silencing complex (RISC complex) is composed
f Dicer and Argonaute protein (AGO).
Hence, siRNA-based therapeutics may offer a safer, effective, and longer-lasting
approach that has demonstrated potential as a more personalized approach in the treatment
of many diseases where enzyme activity is implicated, in which we may include HIV
infections [151,152]. However, some obstacles must be solved before this therapeutic
strategy can be used in clinical settings. These include improving delivery tactics and
lowering costs. During the last decade, several research groups have worked on the topic
of drug/nucleic acid co-delivery, mostly focusing on lipid-based nanocarriers. Indeed,
the use of lipid-based nanocarriers, most commonly cationic charged liposomes or SLN,
have several advantages, such as their ability to complex anionic nucleic acids and to protect
RNAi from serum nucleases degradation and prolong blood circulation, which allows better
distribution into the target tissues [148]. These systems are also essential for intracellular
delivery, working as effective carriers for traversing the cytoplasmic membrane. For example,
Kim et al. formulated a stabilized liposome for systemic administration of siRNA using a
humanized mouse model to target lymphocyte function-associated antigen 1 (LFA-1), i.e.,
the predominant integrin found on all leukocytes. In vivo studies demonstrated a selective
siRNA absorption by T cells and macrophages [153]. The opportunities for such continued
innovation in formulating ARV drugs/nucleic acid co-delivery systems [148,153–155] will
ensure continued research in this field, which should eventually lead to their clinical use.
ARV and siRNA co-delivery has been proposed as a promising biotechnological
strategy for the treatment of Alzheimer’s disease (AD) in a context other than HIV therapy.
The amyloid hypothesis has emerged as the dominant theory to explain the molecular
pathogenicity of AD, following the identification of AβP as the plaque-forming peptide
aggregated and accumulated in the brain, and amyloid-β precursor protein (APP) as
the gene locus responsible for amyloid β-peptide (AβP) production [156]. Accumulated
plaques cause hyperphosphorylation of the microtubule-associated protein tau, which
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aggregates to form neurofibrillary tangles (NFT), synaptic dysfunction, cell death, and,
eventually, AD [156]. Despite evidence supporting the amyloid hypothesis, many clinical
trials focusing on Aβ components have failed to produce any AD-modifying therapies [156].
It has recently been discovered that SGR retro-inserts novel genomic complementary DNA
into neuronal genomes and becomes dysregulated in AD, producing numerous APP variant
genes, transcripts, and AβP that would remain in the brain in various potential forms
(e.g., plaques, fibrils, prions, and soluble products) and may not be recognized by specific
Aβ-antibodies used in the therapeutic attempts to target AβP [156,157]. As a result, SGR
provides a novel mechanism for explaining AD pathogenesis and the failures of Aβ-related
clinical trials [156,157].
Human epidemiological data on 100,000 older HIV-infected patients (>=65 years old)
revealed that the world population’s 10 percent prevalence of AD was not confirmed in
these patients [156]. In fact, 1000 HIV-infected patients with AD were expected, but only
one documented AD/HIV-infected case occurred [156]. This finding supports the notion
that brain RT is involved in SGR, and its inhibition by ARV drugs or the silencing of its
expression by siRNA is recently seen as a possible AD preventive and/or therapeutic
intervention.
5. Conclusions
Notwithstanding the cART overall success, it continues to raise some serious concerns,
and its effectiveness is hampered by some limitations such as ARV resistance mechanisms,
prolonged treatment regimens, drug-drug interactions, toxicity effects, and pharmacoki-
netics issues. Therefore, innovative strategies such as lipid-based nanocarriers for ARV
delivery appear to overcome physiological barriers. However, many issues must be ad-
dressed before we can reap the benefits of appropriate nanotechnology-based delivery
systems that could improve ARV therapeutic outcomes. To begin with, most studies do not
provide a thorough characterization of the lipid-based nanosystems developed or provide
an incomplete or non-systematic formulation development methodology. Indeed, most
studies do not consider the impact of nanosystems’ composition on: (i) ARV encapsulation
and loading efficiency; (ii) nanosystems’ size and surface charge potential; (iii) nanosys-
tems’ ability to completely release the entrapped bioactives; and, finally, (iv) nanosystems’
efficiency to deliver ARV to the virus reservoirs where their effects should be evaluated.
Biotechnological applications of lipid nanocarriers loaded with anti-HIV therapeutics, such
as the use of lipoplexes for siRNA delivery for AD, were also discussed. This promising
bidirectional strategy helps ARV cross the BBB while halting SGR genome mutations that
appear to be the cause of therapeutic AD failures.
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